Novedades en hipertensión arterial y riesgo vascular: Mayo-Junio 2023

Los días 23 – 26 de Junio de 2023 tendrá lugar en Milán el 32nd European Meeting on Hypertension and Cardiovascular Protection, organizado por la European Society of Hypertension.  En este congreso se presentarán las nuevas Guías Europeas de Hipertensión Arterial (ESH 2023).
Saturday, June 24, 16:15 – 17:45
SILVER HALL – ESH 2023 GUIDELINES. GENERAL ASPECTS – Plenary Session 1
Últimas publicaciones relevantes en el campo de la HTA:
Mulligan MD, Murphy R, Reddin C, Judge C, Fegurson J, Alvarez-Iglesias A, et al. Population attributable fraction of hypertension for dementia: global, regional, and national estimates for 186 countries. eClinicalMedicine 2023;60:102012.
SUMMARY
Background: Quantifying the proportion of dementia attributable to highly prevalent modifiable risk factors, such as hypertension, is important in informing effective dementia prevention strategies. We aim to quantify the population attributable fraction (PAF) of hypertension for dementia (the proportion of dementia cases that would not occur if hypertension was eliminated) at global, regional, and national levels.
Methods: In this study, we searched international and governmental websites for global, regional, and national data reporting population hypertension (according to 10-year age categories) and dementia prevalence. MEDLINE was searched for studies reporting the risk of dementia from age at hypertension diagnosis from database inception to December 31, 2022. Longitudinal observational studies with >500 participants reporting hazard ratios by age at hypertension diagnosis for risk of future all-cause dementia were eligible for inclusion. Studies excluded had cross-sectional methodology, specific vascular dementia or ‘cognitive impairment’ outcomes, and no age-specific metrics of association reported. The PAF of hypertension for dementia was calculated globally and for each country and region worldwide.
Findings: Data from the Global Burden of Disease, United Nations Population Prospectus, NCD Risk Factor Collaboration, UK Biobank, and Atherosclerosis Risk in Communities Study were obtained. 186 countries reported dementia and hypertension prevalence data. The global PAF of hypertension for dementia was 15.8% [95% Credible Interval (CI), 8.8%–22.7%]. Latin America and the Caribbean (18.0% [95% CI, 9.4%–26.6%]), and Europe (17.2% [95% CI, 9.6%–24.7%]) had the highest PAF of hypertension for dementia. Hypertension diagnosed between the ages of 30–44 had the highest age-specific global attributable fraction for dementia (8.4% [95% CI, 3.4%–13.5%]), followed by ages 45–54 (2.92% [ 95% CI, 0.96%–4.88%]), 55–64 (2.59% [95% CI, 1.15%–4.03%]) and 65–74 (1.82% [95% CI, −2.31%–5.96%]).
Interpretation: The population attributable risk of hypertension for dementia is 15.8%, suggesting that optimal detection and treatment, particularly at midlife, has the potential to markedly reduce the global burden of dementia.
Comentario: Publicaciones previas de los últimos años, han resaltado la relevancia de diagnosticar y tratar precozmente la HTA, especialmente en los jóvenes y en la edad media de la vida, para poder prevenir de forma adecuada la alteración cognitiva futura. Cuando el tratamiento se inicia en edades posteriores de la vida, el beneficio en la prevención de la demencia queda notablemente reducido.
Adjunto las referencias de 2 editoriales recientemente publicadas por nuestro grupo sobre dicho tema, para tener la oportunidad de poder ampliar la información al respecto:
Armario P, Gómez-Choco M. It is possible to prevent cognitive decline among middle-aged and older hypertensive individuals ?. Hypertens Res 2022;45:1079-1081
Armario P, Gómez-Choco M. Contributions of neuroimaging to the knowledge of the relationship between arterial Hypertension and cognitive decline. Hypertens Res 2023;46:1344-1346